Ashkan Khavaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ashkan Khavaran has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ali Rastegar-Kashkouli
Kowsar Hospital, Fars Heart Foundation, Research Committee, Shiraz, Iran
2 shared publications - Barbara Hummel
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
2 shared publications - Dordaneh Rastegar
Nickan Research Institute, Isfahan, Iran
2 shared publications - Fernando Aprile-Garcia
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
2 shared publications - Mohsen Jafari
Abu-Ali Sina Organ Transplant Hospital, Research Committee, Shiraz, Iran
2 shared publications - Pourya Yousefi
Kowsar Hospital, Fars Heart Foundation, Research Committee, Shiraz, Iran
2 shared publications
Latest Publications
- Open Access
- 3 June 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 12 (2) , e10604
Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.
- 3 June 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 12 (2) , e10604
Open AccessAssociation between type 2 diabetes mellitus and multiple myeloma: Fact or fiction
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.
- Open Access
- 1 April 2023
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 11 (1) , e11199
Current status and perspectives of ultrasound-guided ablation techniques in patients with primary hyperparathyroidism
Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.
- 1 April 2023
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 11 (1) , e11199
Open AccessCurrent status and perspectives of ultrasound-guided ablation techniques in patients with primary hyperparathyroidism
Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.
- Open Access
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (6) , 1645-1659.e9
Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (6) , 1645-1659.e9
Open AccessHeat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1
- Open Access
- 4 February 2019
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 26 (2) , 137-146
Nascent-protein ubiquitination is required for heat shock–induced gene downregulation in human cells
Proteotoxic stress such as heat shock causes heat-shock factor (HSF)-dependent transcriptional upregulation of chaperones. Heat shock also leads to a rapid and reversible downregulation of many genes, a process we term stress-induced transcriptional attenuation (SITA). The mechanism underlying this conserved phenomenon is unknown. Here we report that enhanced recruitment of negative transcription elongation factors to gene promoters in human cell lines induces SITA. A chemical inhibitor screen showed that active translation and protein ubiquitination are required for the response. We further find that proteins translated during heat shock are subjected to ubiquitination and that p38 kinase signaling connects cytosolic translation with gene downregulation. Notably, brain samples of subjects with Huntington’s disease also show transcriptional attenuation, which is recapitulated in cellular models of protein aggregation similar to heat shock. Thus our work identifies an HSF-independent mechanism that links nascent-protein ubiquitination to transcriptional downregulation during heat shock, with potential ramifications in neurodegenerative diseases.
- 4 February 2019
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 26 (2) , 137-146
Open AccessNascent-protein ubiquitination is required for heat shock–induced gene downregulation in human cells
Proteotoxic stress such as heat shock causes heat-shock factor (HSF)-dependent transcriptional upregulation of chaperones. Heat shock also leads to a rapid and reversible downregulation of many genes, a process we term stress-induced transcriptional attenuation (SITA). The mechanism underlying this conserved phenomenon is unknown. Here we report that enhanced recruitment of negative transcription elongation factors to gene promoters in human cell lines induces SITA. A chemical inhibitor screen showed that active translation and protein ubiquitination are required for the response. We further find that proteins translated during heat shock are subjected to ubiquitination and that p38 kinase signaling connects cytosolic translation with gene downregulation. Notably, brain samples of subjects with Huntington’s disease also show transcriptional attenuation, which is recapitulated in cellular models of protein aggregation similar to heat shock. Thus our work identifies an HSF-independent mechanism that links nascent-protein ubiquitination to transcriptional downregulation during heat shock, with potential ramifications in neurodegenerative diseases.